Sarafan ChEM-H
Showing 81-100 of 192 Results
-
KC Huang
LeRa Professor and Professor of Microbiology and Immunology
Current Research and Scholarly InterestsHow do cells determine their shape and grow?
How do molecules inside cells get to the right place at the right time?
Our group tries to answer these questions using a systems biology approach, in which we integrate interacting networks of protein and lipids with the physical forces determined by the spatial geometry of the cell. We use theoretical and computational techniques to make predictions that we can verify experimentally using synthetic, chemical, or genetic perturbations. -
Adrian Hugenmatter
Director of Protein Engineering
BioDr. Adrian Hugenmatter joined ChEM-H as Director of Protein Engineering in 2021. In his role, Dr. Hugenmatter heads the Protein Engineering Laboratory at the Nucleus and is responsible for the development of therapeutic proteins at the Innovative Medicines Accelerator (IMA). Dr. Hugenmatter obtained his PhD in the laboratory of Prof. Donald Hilvert at the Swiss Federal Institute of Technology in Zurich (ETH Zurich, Switzerland), where he gained initial experience in the fields of enzymology, antibody engineering and directed evolution. Fascinated by protein engineering, he moved to the laboratory of Prof. Dan Tawfik at the Weizmann Institute of Science (Israel), where he studied molecular evolution and its application in protein design. Dr. Hugenmatter then worked for more than a decade as a researcher and team leader at Roche. During this time, he was involved in the development and optimization of several antibody lead candidates for therapeutic applications in neuroscience and oncology.
-
Paul S Humphries
Alliance Director, Innovative Medicines Accelerator (IMA)
Current Role at StanfordAlliance Director, Stanford Innovative Medicines Accelerator (IMA)
-
Peter K. Jackson
Professor of Microbiology and Immunology (Baxter Labs) and of Pathology
Current Research and Scholarly InterestsDr. Jackson’s lab studies how primary cilia organize hormone, metabolite, and growth factor signaling in metabolic tissues and how their disruption causes obesity and diabetes. A second focus is defining the KRAS driven secreted factor networks that rewire the tumor microenvironment in lung and pancreatic cancers to promote immune evasion and therapeutic resistance. This work is revealing new secreted drug targets and combination strategies for precision oncology and metabolic disease.
-
Christine Jacobs-Wagner
Dennis Cunningham Professor, Professor of Biology and of Microbiology and Immunology
BioChristine Jacobs-Wagner is a Dennis Cunningham Professor in the Department of Biology and the ChEM-H Institute at Stanford University. She is interested in understanding the fundamental mechanisms and principles by which cells, and, in particular, bacterial cells, are able to multiple. She received her PhD in Biochemistry in 1996 from the University of Liège, Belgium where she unraveled a molecular mechanism by which some bacterial pathogens sense and respond to antibiotics attack to achieve resistance. For this work, she received multiple awards including the 1997 GE & Science Prize for Young Life Scientists. During her postdoctoral work at Stanford Medical School, she demonstrated that bacteria can localize regulatory proteins to specific intracellular regions to control signal transduction and the cell cycle, uncovering a new, unsuspected level of bacterial regulation.
She started her own lab at Yale University in 2001. Over the years, her group made major contributions in the emerging field of bacterial cell biology and provided key molecular insights into the temporal and spatial mechanisms involved in cell morphogenesis, cell polarization, chromosome segregation and cell cycle control. For her distinguished work, she received the Pew Scholars award from the Pew Charitable Trust, the Woman in Cell Biology Junior award from the American Society of Cell Biology and the Eli Lilly award from the American Society of Microbiology. She held the Maxine F. Singer and William H. Fleming professor chairs at Yale. She was elected to the Connecticut academy of Science, the American Academy of Microbiology and the National Academy of Sciences. She has been an investigator of the Howard Hughes Medical Institute since 2008.
Her lab moved to Stanford in 2019. Current research examines the general principles and spatiotemporal mechanisms by which bacterial cells replicate, using Caulobacter crescentus and Escherichia coli as models. Recently, the Jacobs-Wagner lab expanded their interests to the Lyme disease agent Borrelia burgdorferi, revealing unsuspected ways by which this pathogen grows and causes disease -
Amy Jacobson
Director of Microbiome Therapies, Microbiome Therapies Initiative (MITI)
Current Role at StanfordSenior Scientific Program Manager, Sarafan ChEM-H and Stanford Innovative Medicines Accelerator
-
Daniel Jarosz
Senior Associate Dean, Basic Science, Professor of Chemical and Systems Biology and of Developmental Biology
Current Research and Scholarly InterestsMy laboratory studies conformational switches in evolution, disease, and development. We focus on how molecular chaperones, proteins that help other biomolecules to fold, affect the phenotypic output of genetic variation. To do so we combine classical biochemistry and genetics with systems-level approaches. Ultimately we seek to understand how homeostatic mechanisms influence the acquisition of biological novelty and identify means of manipulating them for therapeutic and biosynthetic benefit.
-
Michael Christopher Jewett
Professor of Bioengineering and, by courtesy, of Chemical Engineering
BioMichael Jewett is a Professor of Bioengineering at Stanford University. He received his B.S. from UCLA and PhD from Stanford University, both in Chemical Engineering. He completed postdoctoral studies at the Center for Microbial Biotechnology in Denmark and the Harvard Medical School. Jewett was also a guest professor at the Swiss Federal Institute of Technology (ETH Zurich). His research group focuses on advancing synthetic biology research to support planet and societal health, with applications in medicine, manufacturing, sustainability, and education.
-
Chaitan Khosla
Wells H. Rauser and Harold M. Petiprin Professor and Professor of Chemistry and, by courtesy, of Biochemistry
Current Research and Scholarly InterestsResearch in this laboratory focuses on problems where deep insights into enzymology and metabolism can be harnessed to improve human health.
For the past two decades, we have studied and engineered enzymatic assembly lines called polyketide synthases that catalyze the biosynthesis of structurally complex and medicinally fascinating antibiotics in bacteria. An example of such an assembly line is found in the erythromycin biosynthetic pathway. Our current focus is on understanding the structure and mechanism of this polyketide synthase. At the same time, we are developing methods to decode the vast and growing number of orphan polyketide assembly lines in the sequence databases.
For more than a decade, we have also investigated the pathogenesis of celiac disease, an autoimmune disorder of the small intestine, with the goal of discovering therapies and related management tools for this widespread but overlooked disease. Ongoing efforts focus on understanding the pivotal role of transglutaminase 2 in triggering the inflammatory response to dietary gluten in the celiac intestine. -
Peter S. Kim
Virginia and D. K. Ludwig Professor of Biochemistry
Current Research and Scholarly InterestsOur research focuses on developing new strategies for vaccine creation. We also aim to generate vaccines targeting infectious agents that have eluded efforts to date. We integrate experimental approaches with protein language models to guide artificial evolution and enable efficient antibody and protein engineering. Our interdisciplinary approach aims to address critical global health challenges.
-
Bruce Koch, Ph.D.
Director of High-Throughput Screening
Current Role at StanfordDirector, ChEM-H/CSB High Throughput Screening Group
Staff Lead, IMA HTS Module
Adviser to the SPARK Program -
Pallavi Kompella
Lead Research Scientist, Animal Pharmacology, Innovative Medicines Accelerator (IMA)
BioPh.D. Pharmaceutical Sciences, The University of Texas at Austin, Texas
(American Foundation for Pharmaceutical Education Doctoral Fellow)
Fulbright Postdoctoral Scholar, Biomedical Research Institute of Malaga, Spain -
Siddharth Krishnan
Assistant Professor of Electrical Engineering, and by courtesy, of Bioengineering and of Materials Science and Engineering
Current Research and Scholarly InterestsThe Krishnan Lab develops bioelectronic devices, tools and systems for closed loop disease management. Our work is divided into the following broad areas:
1. Biohybrid electronics for therapy and sensing: we combine living cells as functional parts of implantable devices, leveraging their ability to produce complex biologic therapeutics in a constitutive or triggerable manner, and their ability to sense their complex dynamic environment. These efforts are focused on developed functional cures for diseases like Type I Diabetes and other conditions requiring the regular infusion of proteins, peptides or antibody drugs.
2. Digital drug release systems for particulate forms of biologic drugs: Many complex protein and peptide drugs are not stable in solution, thereby frustrating the ability to delivery them through pumps and autoinjectors. This need is particularly acute for drugs that need to be administered as emergency rescue therapies, such as glucagon in the context of type 1 Diabetes. We develop implantable, miniaturized microelectromechanical devices that can store particulate (powders, pills) forms of these drugs and release them in a close loop manner based on wireless inputs from sensors.
3. Wearable sensors: Wearables to detect biophysical (temperature, flow, cardiac activity) and biochemical markers of health are gaining importance for closed-loop disease management and personalized medicine. We design hardware for on-chip molecular profiling based on sampling biofluids in noninvasive or minimally invasive formats.
4. New wireless power architectures for implantable bioelectronics: We develop high-power, high-efficiency strongly coupled power harvesting system to power battery-free implant systems.
